<DOC>
	<DOCNO>NCT02287818</DOCNO>
	<brief_summary>AC-201CR control release formulation AC-201 previous clinical study show potential dual effect reduce serum uric acid ( sUA ) gout flare . The mechanism action AC-201 include inhibition production activity caspase-1 interleukin-1β ( IL-1β ) , selective inhibition re-absorption transporter kidney . The goal gout treatment reduce serum uric acid ( sUA ) concentration urate solubility limit avoid acute gout flare . However , initiation urate-lowering therapy ( ULT ) increase occurrence acute gouty arthritis flare . IL-1β play key role mediate inflammatory response . The study design test urate-lowering effect , safety , tolerability AC-201CR initial dosing period , follow addition ULT test efficacy safety combination prophylaxis gout flare ULT .</brief_summary>
	<brief_title>A Study AC-201 Controlled-Release Tablet ( CR Tablet ) Patients With Gout</brief_title>
	<detailed_description />
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . Male female age 20 65 year , inclusive . 2 . Meets ≥6 12 American College Rheumatology preliminary criterion ( 1977 ) classification acute arthritis primary gout ( Appendix 2 ) , OR proven tophus documented monosodium urate ( MSU ) crystal joint fluid . 3 . Serum uric acid ≥7.5 mg/dL ≤10 mg/dL screen ≥1 gouty arthritis flare within one year prior screening , OR serum uric acid ≥9 mg/dL ≤10 mg/dL screen without prior gout flare . 1 . Use allopurinol , febuxostat , benzbromarone , probenecid , sulfinpyrazone within 2 week prior screen . 2 . Occurrence gouty arthritis flare within 1 week prior screen screen period baseline . 3 . Use colchicine within 1 week prior screen . 4 . Use Glucocorticoids , NSAIDs COX2 inhibitor within 1 week prior screen . 5 . Allergy , contraindication , intolerance febuxostat . 6 . Severe renal impairment . 7 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) concentration &gt; 2 time upper limit laboratory normal range ( &gt; 2x ULN ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>